We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04839341
Recruitment Status : Recruiting
First Posted : April 9, 2021
Last Update Posted : September 16, 2021
Sponsor:
Collaborator:
Zhejiang CrownMab Biotech Co. Ltd
Information provided by (Responsible Party):
Apollomics Inc.

Brief Summary:
This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.

Condition or disease Intervention/treatment Phase
Relapsed/Refractory AML Drug: Uproleselan Phase 1

Detailed Description:

This study is a multicenter open-labelled study conducted in subjects with relapsed or refractory AML in China. The study includes the following phases: screening phase, induction phase, consolidation phase baseline, consolidation phase and follow-up period.

Screening phase:

This study will enroll 12 subjects, who are 18 to 60 years (inclusive) at the time of signing the Informed Consent Form (ICF), and with the diagnosis as relapsed or refractory AML. Screening is conducted 21 days to 2 days before administration, and signed ICF by the subject must be obtained before screening.

Baseline period:

The baseline period is 1 day before study drug administration.

Induction treatment:

During the induction phase, subjects will receive 8 consecutive days of uproleselan treatment and 5 consecutive days of MEC (mitoxantrone, etoposide, and cytarabine combined regimen) chemotherapy.

Consolidation baseline:

The baseline of the consolidation phase is 1 day before the treatment administration of the consolidation phase.

Consolidation treatment:

Subjects who met the criteria for consolidation treatment started the consolidation period at the 29th day of the previous treatment cycle at the earliest and the 65th day at the latest.

Follow-up period:

Each subject should complete the following follow-up stage: (1) Response evaluation to determine remission to the induction treatment (induction period); (2) EOT assessment after completing the last consolidation treatment cycle; (3) Death. Survival and long-term follow-up, including initiation of new anti-leukemia treatment (within 6 months after the last uproleselan/placebo administration), recurrence, HSCT and survival events, monthly (±14 days) for 2 years after the end of treatment, and afterwards quarterly (±14 days). The longest survival follow-up time is 3 years (calculated from the start of treatment).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Open-labeled Multicenter Study to Determine Pharmacokinetics, Safety, Tolerability and Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
Actual Study Start Date : February 24, 2021
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : February 28, 2023


Arm Intervention/treatment
Experimental: A Phase I, open-labeled multicenter study
Uproleselan in combination with mitoxantrone, etoposide and cytarabine (MEC)
Drug: Uproleselan
A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
Other Name: GMI-1271




Primary Outcome Measures :
  1. Peak plasma concentration (Tmax) [ Time Frame: 14 days ]
    To assess the pharmacokinetic profile in patients with relapsed/refractory AML.

  2. Peak plasma concentration (Cmax) [ Time Frame: 14 days ]
    To assess the pharmacokinetic profile in patients with relapsed/refractory AML.

  3. Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12) [ Time Frame: 14 days ]
    To assess the pharmacokinetic profile in patients with relapsed/refractory AML.

  4. The area under the plasma concentration-time curve (AUC0-t) from time zero to the last measurable time point [ Time Frame: 14 days ]
    To assess the pharmacokinetic profile in patients with relapsed/refractory AML.

  5. The Incidence of Adverse Events [ Time Frame: Up to 10 months ]
    Number of participants with an AE.

  6. The tolerance of participants with relapsed/refractory AML. [ Time Frame: Up to 10 months ]
    Number of participants could tolerate the Uproleselan combined with chemotherapy.


Secondary Outcome Measures :
  1. OS [ Time Frame: Up to 3 years ]
    Defined as the period from when the subject receives the first dose of the study drug to death from any cause;

  2. Remission rate (rate of CR, CR/CRi and CR/CRh) [ Time Frame: Up to 60 days ]
    Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh;

  3. CTCAE grade 3 and 4 oral mucositis [ Time Frame: Up to 254 days ]
    The incidence of CTCAE grade 3 and 4 oral mucositis during the treatment duration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Key Criteria:

  1. ≥18 years and ≤60 years in age
  2. AML (including secondary AML) diagnosed as per WHO standards (2008).
  3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy.

    1. For relapse AML, it must be the first or second relapse, and remain untreated.
    2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed.
  4. ECOG performance status score is 0 to 2.
  5. Stable hemodynamics and good organ function and good organ function.

Exclusion key Criteria:

  1. Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.
  2. Active signs or symptoms of CNS involvement by malignancy.
  3. Stem cell transplantation ≤4 months prior to dosing.
  4. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
  5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
  6. Inadequate organ function.
  7. Abnormal liver function.
  8. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
  9. Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
  10. Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
  11. Clinically significant cardiovascular disease.
  12. Major surgery within 4 weeks of dosing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04839341


Contacts
Layout table for location contacts
Contact: Zhejiang CrownMab Ltd. 0571-83521933 ClinicalTrialsChina@apollomicsinc.com
Contact: Qian Li 0571-83521933 Qian.li@apollomicsinc.com

Locations
Layout table for location information
China, Tianjin
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Recruiting
Tianjin, Tianjin, China, 300020
Contact: Jianxiang Wang, Phd    022-23909120    wangjx@medmail.com.cn   
China
The First Affiliated Hospital of Zhejiang University Recruiting
Hangzhou, China
Contact: Jie Jin, PhD    057187236685    jiej0503@zju.edu.cn   
Sponsors and Collaborators
Apollomics Inc.
Zhejiang CrownMab Biotech Co. Ltd
Investigators
Layout table for investigator information
Principal Investigator: Jianxiang Wang, Phd Investigator
Layout table for additonal information
Responsible Party: Apollomics Inc.
ClinicalTrials.gov Identifier: NCT04839341    
Other Study ID Numbers: APL-106-01
First Posted: April 9, 2021    Key Record Dates
Last Update Posted: September 16, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Apollomics Inc.:
AML